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Abstract. Background/Aim: Structural modifications of
daunorubicin are an important way to change its anticancer
activity. For this reason, formamidinodaunorubicins have been
synthesized. The present study was undertaken to determine and
compare the in vitro effects of daunorubicin and its new
formamidine derivatives on human acute leukemia MOLT-4 and
ML-1 cells. Materials and Methods: The experiments were
performed on human acute lymphoblastic leukemia MOLT-4
cells and human acute myeloblastic leukemia ML-1 cells. The
study was conducted using flow cytometry and light microscopy
methods. Results: The various patterns of temporary changes in
the cell cycle and DNA fragmentation, as well as the extent of
mitotic catastrophe, apoptosis, and necrosis, were determined.
The anti-leukemic activities of the new daunorubicin analogs
were weaker than that of daunorubicin. Conclusion: The
influence of these anthracyclines on cell-cycle progression, DNA
damage, and induction of mitotic catastrophe and cell death
depended on the agent and its concentration, the time interval
after application, and the cell line used. The structural
modifications of daunorubicin were responsible for the different
cytotoxic effects of the two formamidinodaunorubicins.
The anthracycline antibiotic daunorubicin is one of the most
potent anticancer drugs used in cancer chemotherapy (1, 2).
Nevertheless, its clinical efficacy is limited by many serious side-
effects, including cardiotoxicity and development of multi-drug
resistance (3-6). One of the new strategies for cancer treatment is
the design and synthesis of new analogs of daunorubicin, e.g.
formamidinodaunorubicins. In the chemical structure of these
derivatives of daunorubicin, the amidine group is bound to the
daunosamine moiety at C-3’ position (Figure 1) and contains the
rest of the cyclic amines with gradually increasing ring size (7,
8). Literature data suggest that these formamidinodaunorubicins
can be promising anticancer agents (9, 10).
The cell cycle and programmed death are accepted to be
closely linked and regulated (11-14). In normal cells there is a
subtle balance between processes of proliferation and
programmed death. It is postulated that the decision of cell-
cycle-progression or death can result from a conflict of signals
that induce mitotic division and cell-cycle arrest. Mitotic failure
can be caused by DNA damage. Mitotic catastrophe, a process
preceding cell death, can trigger apoptotic and necrotic processes
in the cell. Based on the complex interactions between the
regulatory pathways of the cell cycle and programmed death, the
cell makes a final decision to divide or to die.
Understanding the action of anthracyclines requires
knowledge of the cell-cycle phase at which the cell activates its
suicide machinery in response to DNA-damaging agents and
their ability to induce programmed death (12). However, only
few reports on cell-cycle specificity in terms of DNA damage
by different chemotherapeutic drugs have been published (1, 13,
15). Available information on the influence of the new
formamidine derivatives of daunorubicin on cell death induction
is scarce (16). Moreover, as far as we are aware of, there are no
published data on the effects of the formamidinodaunorubicin
compounds on cell-cycle progression, DNA damage, and
triggering of mitotic catastrophe in human acute leukemia cells. 
The aim of the present study was to determine and compare
the effects of daunorubicin and new formamidine analogs
containing either a morpholine moiety (DAUFmor) or a
hexamethyleneimine moiety (DAUFhex) in the amidine group,
on human acute lymphoblastic leukemia MOLT-4 cells and
human acute myeloblastic leukemia ML-1 cells. The influence
of these two new derivatives of daunorubicin on the cell cycle,
DNA fragmentation, and induction of mitotic catastrophe and
programmed death of these leukemia cells was analyzed.
Materials and Methods
Cells. Human acute lymphoblastic leukemia MOLT-4 cells and human
acute myeloblastic leukemia ML-1 cells were purchased from the
European Collection of Cell Cultures (Salisbury, Wiltshire, UK). Cells
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were cultured in RPMI-1640 medium (Gibco BRL Life Technologies,
Warsaw, Poland) supplemented with 10% fetal calf serum (Gibco BRL
Life Technologies), 2 mM L-glutamine (Sigma Aldrich, Poznań,
Poland), and antibiotic antimycotic solution (AAS; Sigma Aldrich).
AAS contained 20 units of penicillin, 20 μg streptomycin and 0.05 μg
amphotericin B. Every third day, cells were passaged. Cells were
maintained at 37˚C in a humidified atmosphere of 95% air and 5% CO2
(HERAcell incubator; KendroLab, Warsaw, Poland). 
Chemicals. Daunorubicin, and its morpholine derivative (DAUFmor)
and hexamethyleneimine derivative (DAUFhex) were synthesized at the
Institute of Biotechnology and Antibiotics (Warszawa, Poland).
Daunorubicin, DAUFmor and DAUFhex were dissolved in aqua pro
injectione (Polpharma, Starogard Gdański, Poland) at a concentration of
0.5 mM and stored in the dark at −20˚C. All solutions were freshly-
prepared directly before treatment of MOLT-4 and ML-1 cells. 
Anthracycline concentrations and cell treatment. After a dilution of cell
suspension to a density of 15×104 cells/ml medium, MOLT-4 and ML-
1 cells were treated with the tested anthracycline agents. MOLT-4 cells
were exposed to daunorubicin, DAUFmor, and DAUFhex at three
concentrations of 25 nM, 50 nM, and 75 nM, respectively, and ML-1
cells to the action of these anthracycline agents, at concentrations of 75
nM, 150 nM, and 225 nM, respectively. The control material consisted
of untreated MOLT-4 and ML-1 cells. 
Analyses of leukemia cells after anthracycline application. Temporary
changes occurring in MOLT-4 cells and ML-1 cells were determined
at 24, 48, and 72 h after the application of daunorubicin, DAUFmor
and DAUFhex. At these three time intervals, the cell-cycle distribution
and DNA fragmentation were analyzed using a flow cytometric
terminal dUTP nick-end labeling (TUNEL) method, and leukemia cells
undergoing mitotic catastrophe, apoptosis, and necrosis were observed
under a light microscope.
TUNEL assay. TUNEL assay was performed using the APO-BrdU Kit
(Calbiochem, San Diego, USA) according to the manufacturer’s
instructions. Briefly, cells were fixed in 1% formaldehyde, on ice for
15 min, and then stored at −20˚C in 70% ethanol until analysis. Cells
were removed from the ethanol and washed prior to DNA labeling. 
5-Bromo-2’-deoxyuridine 5’-triphosphate nucleotides (Br-dU) were
incorporated onto exposed 3’-hydroxyl DNA ends by incubation with
deoxynucleotidyl transferase TdT for 60 min at 37˚C. Following DNA
labeling, the cells were stained with FITC-labeled anti-BrdU in the dark
for 30 min at room temperature. Finally, the cells were incubated with
RNase/propidium iodide (PI) solution and then incubated in the dark
for 30 min at room temperature. The fluorescence of MOLT-4 and ML-
1 cells stained with FITC-conjugated antibody to BrdU and PI was
detected by a FACS Calibur flow cytometer (Becton Dickinson, New
Jersey, USA). CellQuest Pro software (Becton Dickinson, New Jersey,
USA) was used for acquisition and analysis of data. Temporary changes
in the frequency of all leukemia cells (TUNEL-positive and TUNEL-
negative) and cells expressing DNA strand breaks (TUNEL-positive)
observed in the particular phases of the cell cycle, and in the frequency
of polyploid cells, as well as temporary alterations in the sub-G1
population, were analyzed.
Cell morphology. Leukemia cell suspension, diluted in phosphate
buffered saline (BioMed, Lublin, Poland), containing approximately
2×105 cells, was added into a cytospin chamber and cytocentrifuged
for 6 min at 100 × g and at 4˚C. After air drying, the prepared cytospins
were fixed in methanol at room temperature, for 15 min. Cells were
stained using the Wright-Giemsa method according to the
manufacturer’s instruction (Aqua-Med, Łódź, Poland). Morphological
observations were performed under a light microscope at a
magnification of ×1000. Based on the morphology of leukemia cells,
the frequency of MOLT-4 and ML-1 cells undergoing mitotic
catastrophe, apoptosis, and necrosis was determined.
Statistical evaluation. All experiments were repeated three times with
duplicate or triplicate determinations. All the data are presented as the
mean values±standard deviation. Statistical analyses were performed
using STATISTICA 10 (StatSoft, Kraków, Poland). Data were analyzed
by one-way analysis of variance (ANOVA) followed by Tukey’s
honestly significant differences multiple range test. Results were
considered as significant when the p-value was less than 0.05.
Results
Effects of daunorubicin, DAUFmor and DAUFhex on MOLT-4
and ML-1 cells. The effects of the parent antibiotic daunorubicin
and its two analogs, DAUFmor and DAUFhex, on the cell cycle,
DNA fragmentation, mitotic catastrophe and programmed death
of acute leukemia MOLT-4 and ML-1 cells, were assessed. The
different patterns of temporary changes in the frequency of
leukemia cells in the different phases of the cell cycle, the
frequency of polyploid cells and the sub-G1 population (Figure
2), the frequency of cells with DNA strand breaks (Figure 3)
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Figure 1. Chemical structures of daunorubicin (DAU) and its two
derivatives containing either a morpholine moiety (DAUFmor) or a
hexamethyleneimine moiety (DAUFhex) in the amidine group.
and TUNEL-positive cells found in the different phases of the
cell cycle (Figure 4), as well as the extent of mitotic catastrophe,
apoptosis, and necrosis (Figure 5), were determined throughout
a 72 h period after the application of daunorubicin and
formamidinodaunorubicin agents.
Cell-cycle disturbance. Daunorubicin and its formamidine
derivatives distinctly affected the cell-cycle distribution of the
acute leukemia cells. Daunorubicin caused a blockage of ML-1
cells in the G2/M phase of the cell cycle observed throughout
72 h period, but a decrease of the frequency of MOLT-4 cells
in this phase at 48 h and a 72-h after the parent antibiotic
application. Moreover, an increase of the sub-G1 population was
found at 24 h after the exposure of MOLT-4 cells to the action
of daunorubicin. The cell cycle was disrupted to a lesser extent
by DAU analogs than the parent anthracycline. Among the
daunorubicin derivatives, DAUFmor appeared to be more active
in causing cell-cycle disruption in ML-1 cells than DAUFhex.
Polyploid leukemia cells were observed after the application of
daunorubicin, DAUFmor and DAUFhex. However, the highest
frequency of polyploid cells was observed after the exposure of
ML-1 cells to the action of DAUFmor (Figure 2). 
DNA damage. Daunorubicin induced the formation of DNA
strand breaks in human acute leukemia MOLT-4 and ML-1 cells
to a higher degree than did its analogs, DAUFmor and
DAUFhex. Out of the two derivatives, DAUFmor appeared to
be more active in triggering the formation of DNA strand breaks
than DAUFhex (Figure 3). 
DNA strand breaks in cell-cycle phases. After the application
of daunorubicin and its two analogs, DAUFmor and DAUFhex,
DNA damage was not found to be cell-cycle phase specific. The
results indicate that daunorubicin, DAUFmor and DAUFhex
induced DNA fragmentation in a cell-cycle phase-independent
manner (Figure 4). These three anthracyclines caused DNA
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Figure 2. continued
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Figure 2. Effects of daunorubicin (DAU), and its new derivatives containing either a morpholine moiety (DAUFmor) or a hexamethyleneimine moiety
(DAUFhex) in the amidine group, on the cell-cycle distribution of MOLT-4 and ML-1 leukemia cells. Representative histograms of the cell cycle of
MOLT-4 (A) and ML-1 (B) cells analyzed at 24 h after their exposure to the action of DAU, DAUFmor and DAUFhex. The peaks observed in the channel
FL2-A show leukemia cells, respectively, in G1 phase at a value of 200; and in G2/M phase of the cell-cycle at a value of 400. The compartment below
a value of 200 represents the sub-G1 region which can contain apoptotic bodies or fragments of necrotic cells. The frequency of MOLT-4 (C) and ML-
1 cells (D) in the particular phases of the cell cycle. Values not significantly different at p>0.05 according to the Tukey’s multiple range test: ●, ●●,
●●●. Between the groups of leukemia cells treated with the anthracycline agents; #compared to controls; +between the time points. 
strand breaks in G0/G1, S and G2/M phases of the cell cycle of
MOLT-4 and ML-1 cells. Daunorubicin affected DNA
fragmentation of MOLT-4 and ML-1 cells to a greater degree
than its analogs. In all phases of the cell cycle, a lower
frequency of ML-1 cells with DNA strand breaks was found
than MOLT-4 cells.
Effects of daunorubicin and formamidinodaunorubicins on cell
morphology. After the exposure of MOLT-4 and ML-1 cells to
the action of daunorubicin, DAUFmor and DAUFhex, the
leukemia cells underwent mitotic catastrophe, apoptosis and
necrosis (Figure 5). DAUFmor induced mitotic catastrophe in
leukemia cells to a higher degree than did DAU and DAUFhex,
and this was especially observed in ML-1 cells. Among the
tested anthracyclines, daunorubicin caused an increase of the
frequency of both apoptotic ML-1 cells and necrotic MOLT-4
cells to a greater degree than did its analogs.
Discussion
The effects of daunorubicin and its two formamidine analogs on
cell-cycle disturbance, and induction of mitotic catastrophe and
programmed death of human acute leukemia cells were
compared. The anti-leukemic potential of daunorubicin,
DAUFmor, and DAUFhex towards MOLT-4 and ML-1 cells
depended on the tested compound and its concentration, the time
interval after the anthracycline application, and the cell line used. 
The structural modifications of daunorubicin were responsible
for different anti-leukemic activities of its two analogs against
MOLT-4 and ML-1 cells. Daunorubicin appeared to be more
cytotoxic than its formamidine derivatives. Of the two tested
daunorubicin analogs, DAUFhex, containing a seven-membered
hexamethyleneimine ring with a CH2 group in the γ-position, was
less active than DAUFmor, containing a six-membered
morpholine ring with an oxygen heteroatom in the γ-position in
the formamidine group. The presence of an oxygen heteroatom in
the morpholine ring is probably responsible for forming an
additional hydrogen bond with proton-donating sites, due to the
presence of the free electron pairs on the oxygen atom (9, 10, 16,
17). A number of different mechanisms have been proposed for
the cytotoxic action of daunorubicin, including reactive oxygen
species production, DNA-damage induction, interactions with
DNA topoisomerases I and II, and cell membranes, and also
triggering of programmed cell death (18-21). Nevertheless, the
mechanisms of anticancer activity of the anthracyclines are not
yet completely understood. Available information on the
cytotoxicity of formamidinodaunorubicins is scant (9, 10, 16, 17).
There is a general consensus that DNA is the main target for
a large number of anticancer agents (22, 23). The anthracycline
antibiotics, including daunorubicin, are accepted to be DNA-
damaging agents (18). After the application of daunorubicin and
its new derivatives, DNA strand breaks were observed at all
phases of the cell cycle. Thus, daunorubicin and its formamidine
analogs, DAUFmor and DAUFhex, are non-cell-cycle phase-
specific agents. Moreover, MOLT-4 cells appeared to be more
sensitive to triggering of DNA fragmentation by the tested
anthracycline compounds than ML-1 cells, and daunorubicin
caused DNA degradation to a greater degree than did DAUFmor
and DAUFhex. These results confirmed the data published by
Ciesielska et al. in which daunorubicin induced DNA damage
in leukemia L1210 cells to a greater extent than did DAUFmor
and DAUFhex (24). 
It is known that DNA degradation can affect cell-cycle
progression and inductor of mitotic catastrophe and
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Figure 3. In situ detection of DNA strand breaks in MOLT-4 and ML-1 cells after application of daunorubicin (DAU), and its new derivatives containing
either a morpholine moiety (DAUFmor) or a hexamethyleneimine moiety (DAUFhex) in the amidine group, using flow cytometry APO-BrdU™ assay.
Temporary changes in the frequency of terminal dUTP nick-end labeling (TUNEL)-positive MOLT-4 (A) and ML-1 (B) cells, determined throughout
72 h after DAU, DAUFmor and DAUFhex application. Values not significantly different at p>0.05 according to the Tukey’s multiple range test: ●, ●●,
●●●. Between the groups of leukemia cells treated with the anthracycline agents; #compared to controls; +between the time points. 
programmed cell death (20, 25, 26). The present study shows
that DAUFmor and DAUFhex triggered DNA fragmentation,
which could be responsible for abnormal mitosis, mitotic
catastrophe and cell death shown by the morphology of the
treated leukemia cells.
Mitotic catastrophe is accepted not to be a separate mode of
cell death but rather a process preceding cell death through
apoptosis or necrosis (27). Cells undergoing mitotic catastrophe
originate from abnormal, delayed or abrogated mitosis (26).
One of the most prominent morphological features of mitotic
catastrophe is the presence of multi-nucleated giant cells
possessing abnormal nuclei with incomplete nuclear
condensation and micronuclei. Mitotic catastrophe can also be
manifested by multipolar meta- or anaphase, accidental
distribution of condensed chromosomes, or the formation of
nuclear envelopes around individual clusters of missegregated
uncondensed chromosomes or chromosome fragments (28).
Taking into account these morphological features of the human
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Figure 4. Temporary changes in the frequency of terminal dUTP nick-end labeling (TUNEL)-positive MOLT-4 (A) and ML-1 (B) cells in the particular
phases of the cell cycle, determined throughout the 72 h after daunorubicin (DAU), and its new derivatives containing either a morpholine moiety
(DAUFmor) or a hexamethyleneimine moiety (DAUFhex) in the amidine group application. Values not significantly different at p>0.05 according to
the Tukey’s multiple range test: ●, ●●, ●●●. Between the groups of leukemia cells treated with the anthracycline agents; #compared to controls;
+between the time points. 
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Figure 5. Morphology of MOLT-4 (A) and ML-1 (B) cells at 24 h after their exposure to the action of the three anthracyclines, daunorubicin (DAU),
and its new derivatives containing either a morpholine moiety (DAUFmor) or a hexamethyleneimine moiety (DAUFhex) in the amidine group. MOLT-4
and ML-1 cells, stained with the Wright-Giemsa, were visible under light microscopy. Arrow with bar indicates cells with mitotic catastrophe,
arrowhead indicates apoptotic cells, and long arrow indicates necrotic cells. Scale bar – 10 μm. The frequency of MOLT-4 (C) and ML-1 (D) cells
undergoing mitotic catastrophe, apoptosis, and necrosis. Values not significantly different at p>0.05 according to the Tukey’s multiple range test: 
●, ●●, ●●●. Between the groups of leukemia cells treated with the anthracycline agents; #compared to controls; +between the time points. 
acute leukemia MOLT-4 and ML-1 cells exposed to the action
of daunorubicin and its two formamidine analogs DAUFmor
and DAUFhex, noticeable differences in the extent of mitotic
catastrophe were found.
Apoptosis and necrosis are the two main types of
programmed cell death. The characteristic morphological
features of apoptotic cells includes cell shrinkage, condensation
of chromatin and nuclear fragmentation. Necrotic cells are
characterized by an increased size, cellular membrane
disintegration and nuclear degradation. Daunorubicin,
DAUFmor, and DAUFhex induced both apoptotic and necrotic
death of MOLT-4 and ML-1 cells. The influence of the
anthracyclines, including daunorubicin and doxorubicin, on the
induction of apoptotic and necrotic death of HL-60 and Jurkat
cells was also reported by Dartsch et al. (20).
In conclusion, it can be generally stated that the cytotoxic
effects of daunorubicin, DAUFmor and DAUFhex on MOLT-4
and ML-1 cells depended on their different chemical structures.
These are the first data showing the in vitro effects of new
formamidine derivatives of daunorubicin, DAUFmor and
DAUFhex, on cell-cycle perturbation, DNA damage, induction
of mitotic catastrophe and on triggering morphological alterations
in human acute lymphoblastic MOLT-4 and myeloblastic ML-1
leukemia cells undergoing programmed death. 
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